

# Febre de Origem Indeterminada num Hospital Terciário Português: Um Estudo de Coorte

## *Fever of Unknown Origin in a Portuguese Tertiary Hospital: A Cohort Study*

Mafalda Ferreira<sup>1,2</sup> (<https://orcid.org/0000-0002-7504-3385>), Iolanda Alen Coutinho<sup>1</sup> (<https://orcid.org/0000-0002-2511-4843>), Mariana Lavrador<sup>1</sup>, Odete Duarte<sup>1</sup>, Helder Espert<sup>1,2</sup> (<https://orcid.org/0000-0002-2344-4267>), Armando Carvalho<sup>1,2</sup> (<https://orcid.org/0000-0003-2455-8781>)

### Resumo:

**Introdução:** A febre de origem indeterminada (FOI) mantém-se um verdadeiro desafio diagnóstico apesar dos avanços no campo da medicina. Podem estar na sua origem diversas patologias com prognósticos muito diferentes. Uma reavaliação sobre o tema é essencial considerando as mudanças no curso de várias doenças, assim como a alteração da sua frequência. Este estudo tem por objectivo avaliar a abordagem diagnóstica e etiologias mais frequentes.

**Métodos:** Estudo retrospectivo de doentes admitidos num Serviço de Medicina Interna, de um hospital público terciário, durante 2 anos (2016-2017) que à admissão preenchem os critérios de FOI.

**Resultados:** Foram identificados 55 casos de FOU à admissão (0,6% do total de admissões). As infecções foram a causa mais frequente ( $n = 23$ ; 41,8%) seguida das doenças inflamatórias não infecciosas ( $n = 12$ ; 21,8%), neoplasias ( $n = 8$ ; 14,5%) e outras ( $n = 3$ ; 5,5%). No entanto, em 9 casos o diagnóstico manteve-se desconhecido (16,4%). A doença mais prevalente foi a febre Q, seguida da endocardite bacteriana e abscessos em várias localizações. Foram realizados estudos microbiológicos de urina e sangue em todos os doentes, enquanto os testes serológicos apresentaram uma maior variabilidade. Salienta-se o uso da 18F-fluorodesoxyglucose positron emission tomography (18F-FDG-PET) em 11 (20,0%).

**Conclusão:** As etiologias mais frequentes neste estudo assemelham-se a outros estudos internacionais publicados, apesar da menor amostra. A patologia infecciosa foi a causa mais frequente identificada. Apesar de um número ainda significativo de casos sem diagnóstico, estes apresentaram bom prognóstico.

**Palavras-chave:** Febre de Origem Indeterminada/diagnóstico; Febre de Origem Indeterminada/etiologia.

### Abstract:

**Introduction:** Fever of unknown origin (FUO) remains a major diagnostic challenge, despite advances in the medical field. It can be caused by a broad spectrum of diseases with very different prognostic outcomes. Constant re-evaluation of clinical data is essential considering the dynamic changes in disease patterns. We aim to understand which clinical approach is most commonly used and recognize our local epidemiology in order to improve the diagnostic approach to these patients.

**Methods:** We performed a retrospective study in an internal medicine department of a public tertiary hospital. Clinical records of all patients admitted during 2016 and 2017 were consulted; data from patients that fulfilled FUO criteria were collected.

**Results:** A total of 55 FUO patients were identified (0.6% of all admissions). Infections were the most frequent cause ( $n = 23$ ; 41.8%) followed by non-infectious inflammatory diseases ( $n = 12$ ; 21.8%), malignancies ( $n = 8$ ; 14.5%) and miscellaneous group ( $n = 3$ ; 5.5%). However, in 9 cases (16.4%) the etiology remained unknown. The most common disease causing FUO was Q fever, followed by infective bacterial endocarditis and abscesses in different locations. Microbiological study of urine and blood was performed in all patients, while serological tests showed wider variability. The use of 18F-fluorodesoxyglucose positron emission tomography (18F-FDG-PET) in 11 (20.0%) cases stands out.

**Conclusion:** FUO etiologies in our cohort were comparable to other published studies despite the smaller sample. Infections were the most frequent cause identified. Though a significant number of cases remained unknown, it carried a good prognosis.

**Keywords:** Fever of Unknown Origin/diagnosis; Fever of Unknown Origin/etiology.

### Introduction

Fever of unknown origin (FUO) was first mentioned in 1930 by Alt and Barker,<sup>1</sup> but only in 1961 a standardized clinical definition was made by Petersdorf and Beeson.<sup>2</sup> They defined

<sup>1</sup>Department of Internal Medicine, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

<sup>2</sup>Faculty of Medicine, University of Coimbra, Coimbra, Portugal

<https://doi.org/10.24950/rspm.1650>

FUO as a body temperature higher than 38.3°C on three or more occasions, with more than three weeks of disease duration, and with no established diagnosis after one week of inpatient evaluation.<sup>2</sup> This definition has changed over the years to better define FUO and to allow an improved diagnostic approach. Durack and Street<sup>3</sup> in 1991 changed the study period to 3 days of hospitalization or more than 2 medical visits. Since then, several series have been published with some authors proposing to replace the previously established period time of study with a minimal diagnostic work-up required after which the diagnosis remains unknown.<sup>4-6</sup> The investigations that should be included in this protocol remain a matter of debate.<sup>5</sup> An example of a possible work-up is the proposal defined by Mulders-Manders in 2015<sup>4</sup> and the recent suggested structured approach by Wright and Auwaerter.<sup>7</sup>

Durack and Street further classified FUO into 4 categories: classic, nosocomial, neutropenic, and that associated with HIV infection.<sup>3</sup>

clinical care provided to patients with FUO in our setting.

## Methods

### Study Design and Setting

We conducted a descriptive and retrospective study of patients admitted to an internal medicine department of a tertiary reference university hospital between 1 January 2016 and 31 December 2017.

This is a public hospital which directly serves a population of around 465 000 habitants, and indirectly around 2 million people, according to national data from 2017.

### Study Population

The clinical records of all patients admitted during the study period were consulted to select the FUO cases.

Inclusion and exclusion criteria may be seen in Table 1.

The final diagnose registered in the discharge letter or follow-up appointments was assumed as main outcome. The

**Table 1:** Study criteria

Inclusion Criteria (Durack and Street,1991)	Exclusion Criteria
History of at least 3 weeks of illness with fever > 38,3°C on several occasions and no diagnosis after a minimum diagnostic evaluation of more than 2 outpatient visits or 3 days of in-hospital investigation.	Neutropenic, human immunodeficiency virus (HIV)-associated diseases and nosocomial infections.
	Patients with insufficient basic work-up, even if treated successfully with empiric therapy.
	Patients who died during the initial investigations.

The spectrum of diseases responsible for FUO differs with geographical location, socio-demographic and economic status, age, and other factors.<sup>5,8</sup> Several factors have been shown to influence the diagnosis but these differences are still poorly understood.<sup>5,9</sup>

There are more than 200 possible diagnoses, including typical and atypical manifestations of common disorders but also rare conditions, which makes the clinical approach a challenge.<sup>4,6,10</sup> Infections, neoplasms, non-infectious inflammatory diseases (that comprises connective tissue diseases, vasculitis syndromes, and granulomatous diseases)<sup>11</sup> are the etiologies most frequently observed. However, up to 50% of cases remain unclear.<sup>12,13</sup> The undiagnosed cases are generally described as having a benign course with eventual resolution of symptoms.<sup>6,9,10</sup>

Fever is a common condition present in many illnesses. When fever persists and its origin remains unclear after a thorough investigation, it becomes a challenge even to modern medicine.<sup>7,8</sup>

This study aims to better understand our local epidemiology and which clinical approach is most commonly used. Consequently, we aim to improve the diagnostic approach and

etiologies were divided into 5 types: infections, malignancies, non-infectious inflammatory diseases (NIID), miscellaneous and undiagnosed.

### Data Abstraction and Analysis

FUO cases were identified and included in the study after validation by a second author. Clinical data were anonymized and extracted by the main investigator into a Microsoft Excel spreadsheet.

Information about the diagnosis, duration of illness, length of stay, and the complementary diagnostic tests performed in each case was collected.

Continuous variables were summarized as mean ± standard deviation (*s.d.*), or median and standard deviation. Nominal variables were summarized as counts and percentages.

### Ethical Consideration

The study was approved by the Ethics Committee of the Hospital. All identifiable patient information was anonymized.

## Results

Between January 2016 and December 2017, 9401 adult

**Table 2:** Diagnosis of FUO.

Causes	Number of cases (% of total)
<b>Infectious diseases</b>	23 (41.8)
Q fever	5 (9.1)
Abscesses (liver, spleen, and lung)	4 (7.3)
Infective endocarditis	4 (7.3)
Extrapulmonary tuberculosis	2 (3.7)
Bacteremia ( <i>S. anginosus</i> group)*	1 (1.8)
Bacteremia ( <i>Morganella morganii</i> )*	1 (1.8)
Brucellosis	1 (1.8)
Febrile agranulocytosis related with viral infection (EBV)	1 (1.8)
Legionnaires disease	1 (1.8)
Listeriosis	1 (1.8)
Primary HIV infection	1 (1.8)
Septic spondylodiscitis ( <i>Streptococcus gallolyticus</i> )	1 (1.8)
<b>Non-infectious inflammatory diseases</b>	12 (21.8)
Vasculitic syndromes (giant cell arteritis, Behçet's disease, microscopic polyangiitis)	3 (5.5)
Subacute thyroiditis	2 (3.7)
Acute pericarditis	1 (1.8)
Erythema nodosum	1 (1.8)
Libman-Sacks endocarditis in systemic lupus erythematosus	1 (1.8)
Psoriatic arthritis	1 (1.8)
Rheumatoid arthritis	1 (1.8)
Rheumatoid arthritis-associated usual interstitial pneumonia	1 (1.8)
Sacroiliitis	1 (1.8)
<b>Malignancies</b>	8 (14.5)
Non-Hodgkin lymphoma	3 (5.5)
Colorectal cancer	1 (1.8)
Hodgkin lymphoma	1 (1.8)
Pancreatic cancer	1 (1.8)
Schwannoma	1 (1.8)
Spleen angiosarcoma	1 (1.8)
<b>Miscellaneous</b>	3 (5.5)
Haemophagocytic lymphohistiocytosis	1 (1.8)
Myelodysplastic syndrome	1 (1.8)
Toxic hepatitis	1 (1.8)

\*Bacteremia of unknown primary source

patients were admitted to our internal medicine department. Of these, 55 (0.6%) met the criteria for FUO, 35 in 2016 and 20 in 2017.

Of the 55 patients, 32 (58.2%) were male. The patients had a median age of 57.3 years (ranging from 19 to 93 years); 20 patients were 65-year-old or older (36.4%).

The duration of fever of these patients at the time of hospitalization ranged from more than 2 weeks to 4 years in one case.

The medium follow-up time used in this study was 12 months.

Diagnoses found are listed in Table 2. Infections were the most frequent cause identified ( $n = 23$ ; 41.8%) followed by non-infectious inflammatory diseases ( $n = 12$ ; 21.8%), malignancies ( $n = 8$ ; 14.5%) and miscellaneous group ( $n = 3$ ; 5.5%). However, in 9 cases (16.4%) the diagnosis remained unknown.

In the older group ( $\geq 65$ y) infectious diseases remained the principal diagnosis category ( $n = 10$ ), followed by malignancies ( $n = 3$ ). NIID was represented by two cases in this age group, one case of temporal arteritis and a rheumatoid arthritis-associated usual interstitial pneumonia. A myelodysplastic syndrome was also diagnosed. There were 4 undiagnosed cases.

In our study the most common disease causing FUO was Q fever, the infection caused by the bacteria *Coxiella burnetii* ( $n = 5$ ; 9.1%), followed by infective bacterial endocarditis (*Enterococcus faecalis*, *Brucella*, *Proteus mirabilis* and *Streptococcus viridans*) ( $n = 4$ ; 7.3%) and abscesses in different locations ( $n = 4$ ; 7.3%).

During the initial hospitalization three patients died due to complications. The mortality rate during the follow-up was 16.4%.

Among the 9 patients with undiagnosed FUO, none died during follow-up and 5 showed complete recover. There were 4 cases with recurrence of fever in the first 6 months of follow-up. One of them was treated empirically with broad spectrum antibiotics with resolution.

We highlight two cases of fever and polyarthropathy that were described as probable adult-onset Still's disease. Later, after successive episodes of fever recurrence, CNS lymphoma and an autoimmune hepatitis were diagnosed.

Complete blood count with white blood cell count, routine hematochemical tests with inflammatory markers, including C-reactive protein and/or erythrocyte sedimentation rate were evaluated in all patients (Table 3).

Microscopic urinalysis was evaluated in 46 patients. Microbiological study of urine and blood was performed in all patients, while serological tests showed wider variability.

Serological tests have focused more often on HIV (42; 76.4%) and *Mycobacterium tuberculosis complex* (38; 69.1%) search through interferon gamma release assay (IGRA). Serological tests were also done for hepatitis (39; 70.9%), cytomegalovirus (CMV) (37; 67.3%), *Brucella*, *Rickettsia conorii*, *Borrelia burgdorferi* and *Coxiella burnetii*. Detailed information can be seen in Table 4.

Auto-antibodies immunoassays were done in 28 (50.9%) cases.

Regarding imaging tests, all patients underwent chest radiography and 49 (89.1%) abdominal ultrasounds. Other imaging methods were used depending on the clinical case such as computed tomography scan (CT), magnetic resonance imaging (MRI), echocardiogram, and upper and lower digestive endoscopy.

**Table 3:** Diagnostic workup tests.

<b>Lab tests</b>	
Complete blood count	55(100.0)
C-reactive protein (CRP)	55(100.0)
Microbiological study of urine and blood	55(100.0)
<b>Serological tests</b>	
Microscopic urinalysis	46(83.6)
Serum protein electrophoresis	45(81.8)
Auto-antibodies immunoassay	28(50.9)
Stool microbiology study	3(5.5)
<b>Imaging tests</b>	
Chest radiography	55(100.0)
Abdominal ultrasound	49(89.1)
Computed tomography (CT)	35(63.6)
Echocardiogram	17(30.9)
18F-FDG-PET	11(20.0)
Whole body Leukocyte scintigraphy	7(12.7)
Upper and/or lower digestive endoscopy	5(9.1)
Magnetic resonance imaging (MRI)	4(7.3)
<b>Others</b>	
Bone marrow aspiration	7(12.7)
Skin biopsy	4(7.3)
Liver biopsy	3(5.5)
Lymph node biopsy	3(5.5)

The use of 18F-FDG-PET in 11 (20.0%) cases stands out. Patients performed 18F-FDG-PET in situations where the diagnosis was still unclear. 18F-FDG-PET revealed the presence of an underlying neoplasm in 4 patients; 18F-FDG-PET was not useful in NIID (2 patients), miscellaneous (1 patient), infectious (1 patient) or in undiagnosed situations (3 patients).

In some cases, biopsies and bone marrow aspiration were performed (n = 17; 30.9%).

## Discussion

FUO etiologies in our study are comparable to other published studies (Table 5) despite the smaller sample. We found a greater number of infectious diseases and a smaller number of NIID. This finding was not expected if we consider that infectious diseases are more common in developing countries while in developed countries there is a higher prevalence of NIID.<sup>4</sup> In more recent series, infections continued to comprise a significant percentage of FUO cases, and still represent the first cause of FUO globally.<sup>5</sup>

Although the diagnostic approach can be influenced by several factors, like the income of the country, the distribution of diagnostic categories is relatively similar among developed versus developing countries.<sup>7,12,14</sup> Differences in the definition of FUO used, study design, use of a minimal diagnostic work-up and healthcare systems may be responsible for part of the differences shown in the published studies.

**Table 4:** Serological tests.

	Number of tests (% of total)
Human immunodeficiency virus (HIV)	42(76.4)
Viral hepatitis	39(70.9)
Mycobacterium tuberculosis complex	38(69.1)
Cytomegalovirus (CMV)	37(67.3)
Coxiella burnetii	34(61.8)
Epstein-Barr virus (EBV)	31(56.4)
Rickettsia connori	31(56.4)
Brucella	30(54.5)
Borrelia burgdorferi	29(52.7)
Herpes simplex virus (HSV)	23(41.8)
Syphilis (VDRL test)	23(41.8)
Toxoplasma gondii	17(30.9)
Mycoplasma pneumoniae	16(29.1)
Legionella pneumoniae	12(21.8)
Leptospira	11(20.0)
Chlamydia pneumoniae	9(16.4)
Parvovirus	7(12.7)
Chlamydia trachomatis	6(10.9)
Rubeola	4(7.3)
Bartonella	3(5.5)
Leishmania	3(5.5)
Coxsackie virus	2(3.6)
Dengue virus	2(3.6)
Enterovirus	2(3.6)
Varicela zoster virus	2(3.6)
Adenovirus	1(1.8)
Amoebiasis and fasciolosis	1(1.8)
Campylobacter jejuni	1(1.8)
Chikungunya	1(1.8)
Giardia lamblia	1(1.8)
Human herpesvirus 6	1(1.8)
Human herpesvirus 8	1(1.8)
Listeria monocytogenes	1(1.8)
Malaria	1(1.8)
Measles virus	1(1.8)
Tropheryma whipplei	1(1.8)

Comparing recent case series with older ones, from 70 years ago, infections and miscellaneous categories are now less common. Simultaneously, the NIID and undiagnosed conditions have risen.<sup>5,8</sup> A recent systematic review<sup>5</sup> showed a change in the distribution of etiologies over time. There were trends toward a higher prevalence of infectious diseases in Southern Asia compared to Europe.

The most common cause of infection in our study was Q fever. This can be explained based on local epidemiology factors: our population is mostly from rural areas, and they have frequent contact with domestic animals. Q fever is considered an endemic zoonosis in Portugal and is a mandatory notifiable disease. A recent evaluation shows that in Portugal *C. Burnetii* circulates among several domestic and wild animals.<sup>15</sup>

Medical evaluation of older adult patients requires a different approach from that used in younger ones.

A low NIID prevalence (21.8%) may be due to an inadequate work-up, consistent with a low nuclear medical imaging, autoimmunity and immunological tests, compared to serological and microbiological studies. Cognitive bias, i.e., the idea that fever is synonymous of an underlying infection, cannot be excluded.

The number of cases with no diagnosis (16.4%) was comparable to that found in literature in similar studies (Table 5). The risk of having an undiagnosed FUO is higher in Europe.<sup>5</sup> In these cases it was expected that up to 50% will present spontaneous remission and the prognosis is good.<sup>4</sup> In our cohort 44.4% of patients with undiagnosed fever experienced recurrence of symptoms in the first 12 months of follow up and none died in that period.

In our institution, there is not a standardized protocol for initial assessment of FUO, but a cluster of tests is commonly ordered: complete blood count, CRP, microbiology study of urine and blood, serological tests (including tuberculosis and HIV), chest radiography and abdominal ultrasound. Many papers support the use of a standard initial assessment. Though this can potentially lead to an excessive amount of tests performed it can also increase the diagnostic accuracy.<sup>4,6,11,13</sup> We emphasize that a good clinical history and physical

examination must be carefully done, looking for “potentially diagnostic clues”.

Local epidemiological data is also of utmost importance, especially in lab test selection. A random serological test per se has a low diagnostic yield and a fishing strategy should be avoided.<sup>4</sup> But the use of serological tests aimed towards endemic and frequent infection is effective. In our study 18.1% of the diagnoses were supported in serological tests.

In Portugal tuberculosis is still a public health issue, despite the significant reduction in the last decade. This explains that an IGRA test was ordered in 69.1%. This test indicates a cellular immune response to *Mycobacterium tuberculosis*, but it cannot distinguish between an active or latent infection. In Mediterranean countries, Middle East, and related geographical area<sup>6</sup> infections by *Brucella*, *Leishmania*, and Q fever have a higher incidence.<sup>26</sup>

The knowledge of local epidemiology is also frequently used in empirical antibiotic selection, especially when an infection is suspected, and microbiological and serological tests are still ongoing. In our cohort, we observed that many cases were treated with tetracyclines (particularly doxycycline) in the first days after hospital admission. The treatment decision was generally based on a suspicious clinical history and aimed to improve clinical outcomes.

The availability of radiopharmaceutical scans can improve

**Table 5:** Frequency of diagnoses from selected publications.

Publication (Year) <sup>Ref</sup>	Study period	Geographical area	Model of study	FUO criteria	Number of patients	Infection, %	Neoplastic, %	Non-infectious inflammatory diseases, %	Miscellaneous, %	Undiagnosed, %
Petersdorf et al. 1961 <sup>2</sup>	1952-1957	North America	R	PB	100	39.6	20.9	18.7	20.9	9
Kazanjian et al. 1992 <sup>16</sup>	1984-1990	North America	R	PB	86	33	24	26	5	9
De Kleijn et al. 1997 <sup>11</sup>	1992-1994	Europe	P	PB	167	37.4	18.3	33	11.3	31.1
Vanderschueren et al. 2003 <sup>17</sup>	1991-1999	Europe	P	DS	223	25.6	19.2	36.8	18.4	43.9
Saltoglu et al. 2004 <sup>18</sup>	1994-2002	Middle East	R	PB	87	17.2	18.3	13.7	2.2	7
Ergönül et al. 2005 <sup>19</sup>	1993-1999	Middle East	R	PB/DS	80	52	19	17	3	12
Zenone et al. 2006 <sup>9</sup>	1999-2005	Europe	R	DS	144	30.8	13.1	35.5	20.6	25.7
Bleeker-Rovers et al. 2007 <sup>13</sup>	2003-2005	Europe	P	P	73	16	7	22	4	51
Mansueto et al. 2008 <sup>20</sup>	1991-2002	Europe	R	DS	91	31.8	14.2	12	9.8	31.8
Pedersen et al. 2012 <sup>21</sup>	2005-2010	Europe	R	DS	52	32	13	55	0	21
Vanderschueren et al. 2014 <sup>22</sup>	2000-2010	Europe	R	P	436	17	11	24	9.9	39
Robine et al. 2014 <sup>23</sup>	2002-2012	Europe	R	DS	103	23.5	2.9	30.1	4.9	50.5
Naito et al. 2013 <sup>24</sup>	2011	Far East	R	DS	121	23.1	10.7	30.6	12.4	23.1
Naito et al. 2019 <sup>12</sup>	2016-2017	Far East	P	DS	141	17	15.6	34	12.1	21.3
Yenilmez et al. 2021 <sup>25</sup>	2015-2019	Middle East	R	DS	214	44.9	15.4	11.7	8.4	19.6
Present cohort	2016-2017	Europe	R	DS	55	41.8	14.5	21.8	5.5	16.4

R-Retrospective; P-Prospective; FUO criteria: PB-Petersdorf and Beeson; DS-Durak and Street; P- Personal criteria; NA - Not available

the work-up. Particularly 18F-FDG-PET can locate the potential cause with greater sensitivity (about 85%)<sup>27,28</sup> without loss of specificity compared with other nuclear medicine imaging or other anatomic imaging.<sup>6,7,11</sup> It has the potential to identify focal inflammatory or infectious processes, and so it is especially useful for localizing areas for further evaluation.<sup>29</sup> In our sample, an 18F-FDG-PET scan was conclusive in 36.4% of the cases, where it supported a diagnosis of malignancy. Though it failed to provide or point to a probable diagnosis in the remaining, no neoplasm was misdiagnosed.

This study has several limitations: the number of FUO cases is small which can have under represented some etiologies. FUO cases were identified based on the information described in the discharge letter, some of whom did not had a well-defined period of symptoms; it is possible that some FUO cases were missed. It included only patients admitted to the Internal Medicine Department; patients admitted to other departments (e.g., Infectious Diseases, Rheumatology) or followed as outpatients may yield different causes.

We would like to underline some of the strengths of this study: we found that FUO is more common than we expected (0.6% of all admissions), and that the FUO clinical algorithm is useful and should be applied in every situation where the etiology of the fever is not obvious. As far as the authors know, this is the first study on Portuguese patients and it helps to describe local epidemiology. All the patients were admitted to hospital so this study improves the knowledge about the more complex conditions and more severely ill patients.

## Conclusion

FUO is still a challenging problem, being responsible for 0.6% of all admissions in our department. Infections were the most frequent cause, particularly Q fever. Despite extensive work up a large number of cases remained undiagnosed (16.4%). FUO aetiologies found in our study are comparable to other cohorts published.

We consider that the medical history and physical examination are crucial to approach FUO patients. An initial basic standardized laboratory and imaging study can be useful but it should be directed based on clinical features, organ involvement and local disease prevalence to avoid excessive initial testing. We think that the increase of imaging tests at disposal, of which 18F-FDG-PET/CT stands out, and new laboratory methods will contribute to the reduction of undiagnosed cases.

We hope this article helps to fulfil the gap in the Portuguese medical literature on this topic, its prevalence, causes and diagnostic approach. The diagnostic spectrum of FUO is changing over time. Constant re-evaluation of clinical data is essential considering the dynamic change in disease patterns. ■

### Declaração de Contribuição / Contributorship Statement:

Mafalda Ferreira – Conceção, Interpretação dos dados, Redação do manuscrito.

Iolanda Alen Coutinho, Mariana Lavrador, Odete Duarte - Extração e Interpretação de dados.

Hélder Esperto – Conceção, Interpretação dos dados, Revisão do manuscrito.

Armando de Carvalho – Revisão final do manuscrito

### Responsabilidades Éticas

Conflitos de Interesse: Os autores declaram a inexistência de conflitos de interesse na realização do presente trabalho.

Fontes de Financiamento: Não existiram fontes externas de financiamento para a realização deste artigo.

Confidencialidade dos Dados: Os autores declaram ter seguido os protocolos da sua instituição acerca da publicação dos dados de doentes.

Proteção de Pessoas e Animais: Os autores declaram que os procedimentos seguidos estavam de acordo com os regulamentos estabelecidos pelos responsáveis da Comissão de Investigação Clínica e Ética e de acordo com a Declaração de Helsínquia da Associação Médica Mundial.

Proveniência e Revisão por Pares: Não comissionado; revisão externa por pares.

### Ethical Disclosures

Conflicts of interest: The authors have no conflicts of interest to declare.

Financing Support: This work has not received any contribution, grant or scholarship.

Confidentiality of Data: The authors declare that they have followed the protocols of their work center on the publication of data from patients.

Protection of Human and Animal Subjects: The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).

Provenance and Peer Review: Not commissioned; externally peer reviewed.

### Correspondence / Correspondência:

Mafalda Ferreira - mafalda.alvesferreira@gmail.com

Department of Internal Medicine, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

Praceta Prof. Mota Pinto, 3000-075 Coimbra

Received / Recebido: 11/11/2021

Accepted / Aceite: 12/01/2022

Publicado / Published: 23/06/2022

### REFERENCES

1. Alt HL, Barker MH. Fever of unknown origin. *JAMA*. 1930;94:1457–61
2. Petersdorf RG, Beeson PB. Fever of unexplained origin: report on 100 cases. *Medicine*. 1961; 40:1–30.
3. Durack DT, Street AC. Fever of unknown origin—reexamined and redefined. *Curr Clin Top Infect Dis*. 1991; 11:35–51.
4. Mulders-Manders C, Simon A, Bleeker-Rovers C. Fever of unknown origin. *Clin Med*. 2015; 15:280–4. doi:10.7861/clinmedicine.15-3-280.
5. Fusco FM, Pisapia R, Nardiello S, Cicala SD, Gaeta GB, Brancaccio G. Fever of unknown origin (FUO): which are the factors influencing the final diagnosis? A 2005-2015 systematic review. *BMC Infect Dis*. 2019; 19:653. doi:10.1186/s12879-019-4285-8
6. Knockaert DC, Vanderschueren S, Blockmans D. Fever of unknown

- origin in adults: 40 years on, *J Intern Med*. 2003;253:263-75. doi: 10.1046/j.1365-2796.2003.01120.x.
7. Wright W, Auwaerter PG, Fever and Fever of Unknown Origin: Review, Recent Advances, and Lingering Dogma, *Open Forum Infect Dis*.2020;7: ofaa132. doi:10.1093/ofid/ofaa132.
  8. Kaya A, Ergul N, Kaya SY, Kilic F, Yilmaz MH, Besirli K, et al. The management and the diagnosis of fever of unknown origin, *Expert Rev Anti Infect Ther*. 2013;11:805-15. doi: 10.1586/14787210.2013.814436.
  9. Zenone T. Fever of unknown origin in adults: evaluation of 144 cases in a non-university hospital, *Scand J Infect Dis*. 2006; 38:632-8. doi: 10.1080/00365540600606564.
  10. Cunha BA, Lortholary O, Cunha CB. Fever of unknown origin: a clinical approach, *Am J Med*. 2015;128:1138.e1-1138.e15. doi: 10.1016/j.amjmed.2015.06.001.
  11. de Kleijn EM, Vandenbroucke JP, van der Meer JW. Fever of unknown origin (FUO). I A. prospective multicenter study of 167 patients with FUO, using fixed epidemiologic entry criteria. The Netherlands FUO Study Group, *Medicine*. 1997;76:392-400. doi: 10.1097/00005792-199711000-00002.
  12. Naito T, Tanei M, Ikeda N, Ishii T, Suzuki T, Morita H, et al. Key diagnostic characteristics of fever of unknown origin in Japanese patients: a prospective multicentre study, *BMJ Open*. 2019;9:e032059. doi: 10.1136/bmjopen-2019-032059.
  13. Bleeker-Rovers CP, Vos FJ, de Kleijn EM, Mudde AH, Dofferhoff TS, Richter C, et al. A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol, *Medicine*. 2007;86:26-38. doi: 10.1097/MD.0b013e31802fe858.
  14. Knockaert DC, Vanneste LJ, Bobbaers HJ. Fever of unknown origin in elderly patients, *J Am Geriatr Soc*. 1993;41:1187-92. doi: 10.1111/j.1532-5415.1993.tb07301.x.
  15. Anastácio SF. Coxiella burnetii e febre Q: uma zoonose emergente em Portugal? [academic dissertation] Coimbra: Faculty of Pharmacy,-University of Coimbra;2019. [accessed April 2021]Available at: <https://eg.uc.pt/handle/10316/88804>
  16. Kazanjian PH. Fever of unknown origin: review of 86 patients treated in community hospitals, *Clin Infect Dis*. 1992;15:968-73. doi: 10.1093/clind/15.6.968.
  17. Vanderschueren S, Knockaert D, Adriaenssens T, Demey W, Durnez A, Blockmans D, et al. From prolonged febrile illness to fever of unknown origin: the challenge continues, *Arch Intern Med*. 2003;163:1033-41. doi: 10.1001/archinte.163.9.1033.
  18. Saltoglu N, Tasova Y, Midikli D, Aksu HS, Sanli A, Dündar IH. Fever of unknown origin in Turkey: evaluation of 87 cases during a nine-year-period of study, *J Infect*. 2004 Jan;48(1):81-5. doi: 10.1016/j.jinf.2003.08.006. PMID: 14667795.
  19. Ergönül O, Willke A, Azap A, Tekeli E. Revised definition of 'fever of unknown origin': limitations and opportunities, *J Infect*. 2005;50:1-5. doi: 10.1016/j.jinf.2004.06.007.
  20. Mansueto P, Di Lorenzo G, Rizzo M, Di Rosa S, Vitale G, Rini G, et al. Fever of unknown origin in a Mediterranean survey from a division of internal medicine: report of 91 cases during a 12-year-period (1991-2002), *Intern Emerg Med*. 2008;3:219-25. doi: 10.1007/s11739-008-0129-z.
  21. Pedersen TI, Roed C, Knudsen LS, Annika Loft A, Skinhoj P, Nielsen SD. Fever of unknown origin: A retrospective study of 52 cases with evaluation of the diagnostic utility of FDG-PET/CT, *Scand J Infect Dis*.2012; 44:18-23. doi: 10.3109/00365548.2011.603741
  22. Vanderschueren S, Knockaert D. Tackling fever and inflammation of unknown origin: the do's and don'ts, *Acta Clin Belg*. 2014; 69:412-7. doi: 10.1179/2295333714Y.000000000
  23. Robine A, Hot A, Maucort-Boulch D, Iwaz J, Broussolle C, Sève P. Fever of unknown origin in the 2000s: evaluation of 103 cases over eleven years, *Presse Med*. 2014 ;43:e233-40. doi: 10.1016/j.lpm.2014.02.026.
  24. Naito T, Mizooka M, Mitsumoto F, Kanazawa K, Torikai K, Ohno S, et al. Diagnostic workup for fever of unknown origin: a multicenter collaborative retrospective study, *BMJ Open*. 2013;3:e003971. doi: 10.1136/bmjopen-2013-003971.
  25. Yenilmez E, Kakalicoglu D, Bozkurt F, Filiz M, Akkol Camurcu A, Damar Midik EO, et al. Fever of unknown origin (FUO) on a land on cross-roads between Asia and Europa; a multicentre study from Turkey, *Int J Clin Pract*. 2021;75:e14138. doi: 10.1111/ijcp.14138.
  26. Franco I, Sousa P, Gomes M, Oliveira A, Gaio AR, Duarte R. Social profile of the highest tuberculosis incidence areas in Portugal, *Rev Port Pneumol*. 2016;22:50-2
  27. Dong MJ, Zhao K, Liu ZF, Wang GL, Yang SY, Zhou GJ. A meta-analysis of the value of fluorodeoxyglucose-PET/PET-CT in the evaluation of fever of unknown origin, *Eur J Radiol*. 2011;80:834-44. doi: 10.1016/j.ejrad.2010.11.018.
  28. Takeuchi M, Dahabreh IJ, Nishihashi T, Iwata M, Varghese GM, Terasawa T. Nuclear imaging for classic fever of unknown origin: meta-analysis, *J Nucl Med*. 2016; 57:1913-9. doi: 10.2967/jnumed.116.174391.
  29. Schönau V, Vogel K, Englbrecht M, Wacker J, Schmidt D, Manger B, et al. The value of 18F-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study, *Ann Rheum Dis*. 2018;77:70-7.